Title: Determinants of in-hospital mortality in COVID-19; a prospective cohort study from Pakistan

Samreen Sarfaraz¹, Quratulain Shaikh², Syed Ghazanfar Saleem³, Anum Rahim⁴ Fivzia Farooq Herekar⁵, Samina Junejo⁶, Aneela Hussain⁷

1-Samreen Sarfaraz, FRCP (Glasg)

Infectious Disease Department, The Indus Hospital, Karachi

2- Quratulain Shaikh, FCPS, MSc

Indus Hospital Research Centre, The Indus Hospital, Karachi

3-Syed Ghazanfar Saleem, FCPS

Emergency Department, The Indus Hospital, Karachi

4-Anum Rahim, MBBS, MSc

Indus Hospital Research Centre, The Indus Hospital Karachi

5- Fivzia Farooq Herekar, FCPS

Internal Medicine Department, The Indus Hospital, Karachi

6-Samina Junejo, FCPS

Paediatric infectious Diseases, The Indus Hospital, Karachi

7-Aneela Hussain, FCPS

Infectious Disease Department, The Indus Hospital, Karachi

Corresponding Author:

Samreen Sarfaraz,

Email: samreen.sarfaraz@tih.org.pk

samreen2002@gmail.com

Office Tel: +92(21)35112709-17, Office Fax no.: +92(21)35112718

Cell no.:+923232688200

Postal Address: The Indus Hospital, Plot C-76, Sector 3 1/5, Opposite Korangi Crossing, Karachi -75190.

Word Count of summary: 199

Word count of the text: 2877

References: 40

Tables: 4

Figures: 2

Summary

A prospective cohort study was conducted at the Indus Hospital Karachi, Pakistan between March and June 2020 to describe the determinants of mortality among hospitalized COVID-19 patients. 186 adult patients were enrolled and all-cause mortality was found to be 36% (67/186). Those who died were older and more likely to be males ($p<0.05$). Temperature and respiratory rate were higher among non-survivors while Oxygen saturation was lower ($p<0.05$). Serum CRP, D-dimer and IL-6 were higher while SpO₂ was lower on admission among non-survivors ($p<0.05$). Non-survivors had higher SOFA and CURB-65 scores while thrombocytopenia, lymphopenia and severe ARDS was more prevalent among them ($p<0.05$). Use of non-invasive ventilation in emergency room, ICU admission and invasive ventilation were associated with mortality in our cohort ($p<0.05$). Length of hospital stay and days of intubation were longer in non-survivors ($p<0.05$). Use of azithromycin, hydroxychloroquine, steroids, tocilizumab, antibiotics, IVIG or anticoagulation showed no mortality benefit ($p>0.05$). Multivariable logistic regression showed that age > 60 years, oxygen saturation $<93\%$ on admission, pro-calcitonin > 2 ng/ml, unit rise in temperature and SOFA score, ICU admission and sepsis during hospital stay were associated with higher odds of mortality. Larger prospective studies are needed to further strengthen these findings.

Key Findings

1. Age greater than 60 years is associated with in-hospital mortality among COVID-19 patients
2. Oxygen saturation less than 93% and ICU admission are associated with higher odds of mortality
3. Inflammatory markers including CRP, Ferritin and IL-6 were significantly higher among non-survivors
4. Serum pro-calcitonin greater than 2 ng/ml and sepsis during hospital stay are associated with higher odds of mortality among COVID-19 patients

Introduction

In December 2019 a highly transmissible respiratory illness caused by a novel corona virus, later named severe acute respiratory syndrome coronavirus 2(SARS-Cov-2), originated in Wuhan, China and caused a pandemic by its rapid spread [1]. It has resulted in 79,057,616 infections and 1,737,751 deaths globally as of 24th December 2020. Pakistan ranks 28th among the list of high burden countries with 465,070 confirmed infections and 9,668 deaths as of December 24th which is much lower compared to its immediate neighbours [2]. Our mortality rate of 2% [3] is comparable to the India (1.45%) but lower than Iran (4.68%) and several European countries including UK (3.43%) and Italy (3.52%)[2]. The reasons for this difference in fatality is largely unknown but a multifactorial combination of viral immunogenicity, genetic makeup of the host, demography and seasonal variation may play a role in this [4]. Sind province recorded the country's first case on 26th February 2020 and since then has received 44% of the country's COVID-19 confirmed cases with the largest city Karachi being worst hit [3]. The peak of infection in the first wave reached in mid-June when on average 7000 new infections were recorded in a day and the maximum number of deaths recorded were 153 on 20th June 2020. Major hospitals in all big cities were overwhelmed straining the health infra-structure. The Indus Hospital, Karachi emerged as a front liner with a dedicated isolation unit providing free of cost treatment to the sick COVID-19 patients requiring hospitalization. The hospital worked with the government of Sind as a referral and diagnostic center. The experience was challenging for our physicians and allied health staff. We planned to estimate the in-hospital mortality of COVID-19 in Pakistan and study it's determinants in our patients. Till date there is insubstantial published data on in-hospital mortality from Pakistan. As Pakistan has already entered the second wave now, this data will help in risk stratification and management of COVID-19 patients.

Methods

This prospective cohort study was conducted at the Indus Hospital's COVID isolation unit. The Indus Hospital (TIH) Karachi is a 300 bedded tertiary care hospital set up with public private partnership which provides free of cost services to the people. The COVID unit was initially a 20 bedded dedicated COVID facility established in March 2020, later expanded to 56 beds. All COVID-19 (Nasopharyngeal PCR positive) patients older than 18 years admitted between 19th March and 7th June 2020 were included. The study was approved by the institutional IRB under IRD_IRB_2020_04_002. Demographic information, clinical presentation, laboratory abnormalities including inflammatory markers and imaging results were recorded. Patients were categorized as per WHO definitions into asymptomatic (COVID-19 PCR positive but with no clinical manifestation attributable to COVID-19), mild (symptomatic without evidence of pneumonia), moderate (with clinical signs of pneumonia and oxygen saturation $\geq 90\%$ on room air), severe (signs of pneumonia with respiratory rate ≥ 30 breaths/min or SpO₂ $< 90\%$ on room air) and critical (development of Acute Respiratory Distress Syndrome , septic shock or multi organ dysfunction)[5]. Usually patients who required ventilator and medical support were admitted. Few patients needed admission due to other reasons like emergency surgery, pyelonephritis and routine dialysis and these were also included in the cohort. Patients were enrolled into the study as soon as they were admitted in the COVID unit. Patients were followed till death or discharge from hospital. The primary outcome was all-cause in-hospital mortality while we also compared length of stay, occurrence of in-hospital complications, use of inotropic support and of mechanical ventilation among survivors and non survivors. Data was recorded on a REDCap database and analyzed on Stata14. Continuous variables

were expressed as mean (SD) or median (IQR) as appropriate. Categorical variables were expressed as number (%). Student's t-test or Mann Whitney U test were used to compare continuous data. Chi square or Fischer's Exact test was used to compare categorical data. Univariable binary logistic regression was used to model mortality against the predictors. All variables with p-value <0.10 were considered for multivariable binary logistic regression model in order of significance. Odds ratios and 95% confidence intervals were reported.

Results: The emergency department of Indus hospital, Karachi received 11,855 suspected COVID-19 patients out of which 3,851 tested positive for COVID-19 PCR (positivity rate 32.5%) from 19th March to 7th June 2020 (Fig 1). The median age of those who tested positive for COVID-19 PCR was 35 (IQR=26-50) years. The teleconsultation service set up for COVID-19 at TIH, managed most (3,422; 88%) of these asymptomatic to mild spectrum patients at home through a robust algorithm based system of symptomatic treatment, follow up and counselling. Among the rest 384 (9.9%) needed admission but due to limited bed availability in the isolation unit, only 193 (50%) were admitted while the rest were referred to other isolation units in the city. Seven patients who were admitted at TIH were less than 15 years old hence removed from this analysis. Eventually, 186 participants were included in the cohort. The all-cause in-hospital mortality was 36% (67/186). Those who died had a median age 61.4 years (Table 1) compared to those who survived 51.3 years (p<0.001). Males were more likely to die (77.6% in non-survivors compared to 76.5%, p<0.05) in the study cohort.

Clinical presentation:

Fever, shortness of breath and cough were three most common symptoms in both groups while fatigue was common in non-survivors and vomiting was seen in survivors (p>0.05). Hypertension or diabetes were the most prevalent comorbid conditions (52% vs 36% and 52% vs 37% among non-survivors compared to survivors respectively, p=0.007). Blood pressure and heart rate were similar in the groups but respiratory rate was 32/min in non-survivors while 28/min in survivors, p<0.001). Median peripheral oxygen saturation was 86% among non-survivors compared to 93% among survivors (p<0.00). Temperature was also higher among non-survivors (p=0.003). Admitted patients were usually critical (95% among non-survivors vs 61% among survivors, p<0.001). Majority of non-survivors required non-invasive ventilation in the emergency room (56.7 % vs 42%, p<.0001)

Baseline laboratory parameters and Clinical severity scores:

At admission, the WBC count and absolute neutrophil count was higher among non-survivors (12.5 vs 9.9 X 10⁹ /L, p=0.021) and (10.4 vs 7.9 X 10⁹/L, p<0.001) respectively (Table 2). While absolute lymphocyte count and platelet count was lower among non survivors (0.9 vs 1.1 X 10⁹ /L, p=0.009) and (198 vs 234 X10⁹/L, p=0.045). Neutrophil/Lymphocyte ratio (NLR) was higher among non-survivors (10.7 vs 6.7, p<0.001).

There was no difference in the arterial pH or arterial PCO₂ but arterial pO₂ was lower among non survivors (50.2 vs 65.4 mm Hg, p<0.001). PaO₂/FiO₂ ratio was lower among non-survivors (156.8 vs 230.8, p<0.001). Serum creatinine and arterial lactate were higher amongst non-survivors (1.2 vs 1.0 mg/dl, p=0.002; 2.3 vs 1.7 mmol/L, p=0.001 respectively). Similarly, CRP (175.5 vs 131.9 mg/L,

p=0.008), LDH (555.5 vs 398 U/L, p<0.001), d-Dimer (3729 vs 1257 ng/ml, p=0.001), Ferritin (1315 vs 668.8 ng/ml, p=0.002), IL-6 (78.6 vs 21.8 pg/ml, p<0.001), pro-calcitonin (0.9 vs 0.3 ng/ml, p<0.001) and Troponin-I (18 vs 6 ng/ml, p<0.001) were all higher amongst non-survivors compared to survivors. Non-survivors in our cohort had higher SOFA score, CURB-65 score and Mulbsta scores (6 vs 4, 2 vs 1, 7 vs 4 respectively, p<0.001 for all). Severe ARDS was more prevalent (38.6% vs 13.2%, p=0.001) among non survivors compared to survivors.

Hospital Course and outcome

ICU admission was more common among non-survivors (93.8% vs 34.2%) (Table 3). Hence, invasive ventilation was more frequent among non-survivors too (86.6% vs 6.7%). Most common in-hospital complication was Acute Kidney Injury (58.2% vs 7.6%) in non-survivors.

Use of antibiotics (82% vs 73%, p=0.002), Hydroxychloroquine (HCQ) (59.7% vs 45.4%, p=0.06), Azithromycin (AZT) (55% vs 32.8%, p=0.003), combination of HCQ and AZT (40% vs 21%, p=0.006) and intravenous immunoglobulin (IVIG) (p<0.001) were all associated with mortality in our cohort. Use of therapeutic anticoagulation was associated with mortality (p<0.001). Single dose of Tocilizumab showed no mortality benefit while two doses were associated with mortality (p=0.003). There was no mortality benefit of using methylprednisolone in our patients (p>0.05).

Length of hospital stay was longer in non-survivors (9 days vs 7 days, p=0.007). Most common in-hospital complication among non-survivors compared to survivors was Acute kidney injury followed by septic shock (p<0.001). Most common cause of death was multisystem organ failure (35/67, 56.5%).

Predictors of in-hospital all-cause mortality

Univariable binary logistic regression (Table 4) at a cut-off of p<0.10, showed that age greater than 60 years, diabetes mellitus, unit increase in respiratory rate, temperature, SOFA, CURB-65, Mulbsta scores, oxygen saturation < 93%, NLR greater than 5, thrombocytopenia, multilobar involvement on chest x-ray, unit increase in arterial lactate, CRP higher than 200 mg/L, pro-calcitonin higher than 2 ng/ml, high D-dimer, Ferritin and IL-6 showed high odds of mortality. ICU admission, use of antibiotics, therapeutic anticoagulation, Tocilizumab, IVIG, non- invasive ventilation in emergency room, unit increase in length of stay (days), electrolyte abnormalities, sepsis, cardiac complications and acute kidney injury were associated with high odds of mortality. While unit decrease in lymphocyte count, arterial pO₂, PaO₂/FiO₂ ratio and serum albumin were related to high odds of mortality.

Multivariable binary logistic regression (Fig. 2) using all the above variables in order of significance at a p-value <0.05 showed that age more than 60 years (OR=4.27; 95% CI=1.08-16.8); Oxygen saturation <93% (OR=11.56; 95% CI=1.2-105.9) serum prolactin level higher than 2 ng/ml (OR=31.5; 95% CI=3.4-288.2); unit increase in SOFA score (OR=1.5; 95% CI=1.02-2.23); unit increase in body temperature (OR=2.17; 95% CI= 1.07-4.39); ICU admission (OR=16.9; 95% CI=2.8-100.5) and sepsis (OR=23.6; 95% CI=4.6-119.9) were associated with high odds of mortality.

Discussion:

In this prospective cohort study, we report the clinical attributes and risk factors associated with all-cause mortality among hospitalized COVID-19 patients. We found the all-cause mortality to be 36% which is disproportionately high (88%) in those who were ventilated. It is important to highlight here that our patient pool had more critical patients (approximately 74% of total admitted) with 31% and 19% having moderate and severe ARDS respectively on presentation while 35% needing non-invasive ventilation (NIV) in ER to manage respiratory failure. ICU admission was necessary for 55% of which 35% required mechanical ventilation (MV). Our patient population appears to be sicker compared to the only other unpublished data from the city. The reason for this difference could be admission of non-critical patients for monitoring and isolation since it was a private hospital [6]. On the contrary, as mentioned before, our center is a philanthropic, free of cost referral centre for the underprivileged with limited bed capacity. Hence, admission was strictly reserved for critical patients. The poor survival in ventilated cases, apart from the natural disease process, may be due to poor knowledge of the pathogenic mechanism of respiratory injury in the initial days. Most patients were managed with early ventilator support to avoid fatigue and potential risk of aerosolization of COVID-19 with NIV [7]. Gradual understanding of the disease process has shifted the management strategy from early mechanical ventilation towards use of NIV till tolerated as suggested by the National and International COVID guidelines [3, 5]. Global mortality from COVID-19 varies widely (20% -97%) [8, 9] depending on ICU facilities, ventilator performance, experience of ICU team, patient and disease characteristics, geographic area, seasonality and duration of follow up [4]. High ventilator mortality has been reported even from the best centers in Wuhan (97%), New York (88%), UK (67%) and Italy (53.4%) [10-13] questioning the role of invasive ventilation in COVID-19 management especially in LMIC [14]. Ventilator induced lung injury due to barotrauma, volutrauma, atelectrauma, oxytrauma and infections further jeopardize the outcome of COVID-19 patients [15]. Hospitalized patients with COVID-19 have 5 times higher reported mortality than those with influenza pneumonia [16].

Non-survivors in our study showed worse clinical profile with low oxygen saturation, higher temperature and respiratory rate along with bilateral, multi-lobe infiltrates on chest x-ray and raised inflammatory parameters at presentation. This indicates that they were already in the late phases of CRS at admission [17]. The median time to hospitalization from onset of symptoms was 7 days for both survivors and non-survivors consistent with reported literature [18]. However, why some patients were more prone to develop CRS by day 7 is not clear. Older age and male sex were found to be associated with higher mortality as reported globally [19, 20]. It is important to note that the median age of our overall COVID-19 cohort (3855 patients) was 20 years younger than this subset who got admitted to the isolation unit. This is consistent with the idea that since Pakistan's age composition is largely of younger age group, most people who are infected with COVID-19 go asymptomatic or have mild symptoms [21]. Among the high risk comorbid conditions for COVID-19 listed by CDC, only diabetes was statistically significant in our cohort (crude OR= 1.86;95%CI=1.02-3.42)[22].

Neutrophilia, lymphopenia and thrombocytopenia were more pronounced among non-survivors with NLR > 5 having an odds of 3.64 (95%CI=1.65-8.08). Wu C et al found a significant association between neutrophilia, lymphopenia (peripheral CD3, CD4, and CD8 T-cell counts decreased) and development of ARDS [23]. As observed in literature, CRP, D-dimer and IL-6 were all higher among non-survivors in our cohort [23]. Although baseline pro-calcitonin was low in the cohort overall (median 0.4 ng/ml), value of greater than 2 ng/ml was strongly associated with mortality. It is uncertain whether this suggests secondary bacterial infection or hyper-inflammation as studies have suggested that raised pro-calcitonin as a marker of bacterial infection tends to lose specificity as COVID progresses [20, 23]. Non-survivors in

our cohort developed acute kidney injury, sepsis and multi organ dysfunction syndrome (MODS) more frequently than survivors. Unit increase in SOFA score was associated with high odds of mortality in our data. Since SOFA tends to reflect the effect on multiple organ systems, it has proved to be a better predictor of mortality in COVID-19 [24].

Some desperate therapies used globally including Hydroxychloroquine and azithromycin (alone or in combination), therapeutic anticoagulation, antibiotics, two doses of Tocilizumab and IVIG showed increased odds of mortality which when adjusted for other factors became insignificant in the final model. HCQ despite inhibiting viral replication in vitro [25] did not prove beneficial in RCTs [26], rather proved to be toxic. This led to the FDA revoking its emergency use authorization in June 2020 [27]. AZT is the only effective oral drug for treatment of XDR salmonella [28] and COVID-19 pandemic has led to its mass injudicious use, both over the counter and prescription driven, which may increase antimicrobial resistance in the long run. Studies have failed to demonstrate any benefit of AZT alone [29] or in combination with HCQ [30] with a risk of compounding cardiac toxicity by QTc prolongation [31]. Antibiotics were started in 82.6% of our patients suspecting respiratory bacterial co-infection although only 7% initial blood cultures were positive (most patients were not producing sputum) and markers like WBC count and pro-calcitonin were not elevated in the majority. Literature reports low rates of secondary infection with COVID-19 (only 8% in a review of 9 studies) with paradoxical high consumption (72%) of broad spectrum antibiotics [32]. We believe COVID-19 specific antibiotic stewardship guidance is essential to stop the rampant over-use of antibiotics especially in LMIC countries like Pakistan where AMR is already high. Steroids have shown benefit in severe and critical COVID-19 in the RECOVERY trial [33] and a recent meta-analysis of 7 trials conducted on 1703 patients showed a reduction in 28-day mortality compared with standard care or placebo (32% vs 40%, OR= 0.66, 95% CI=0.53-0.82)[34]. However, most experience is with dexamethasone and not methyl prednisolone although MP has been recommended as an alternate to dexamethasone in a dose of 32mg/d in current guidelines [35]. Our patient population was given MP but in higher doses (40mg q8hrs) which may have resulted in the observed hyperglycemia, secondary infections and electrolyte imbalance in our data. Moreover, a randomized trial on severe COVID-19 patients in Brazil did not show any mortality benefit of MP at 28 days as compared to placebo (37% vs 38%)[36]. Some observational studies have reported mortality benefit of TCZ [37, 38] but RCTs failed to demonstrate any difference in survival when compared to placebo or usual care [39]. Data from our center also did not show any survival benefit of TCZ [40].

The final model showed that the factors associated with mortality are older age, low oxygen saturation, high SOFA scores, raised pro-calcitonin, ICU admission and sepsis. This is the first prospective cohort study from Pakistan on in-hospital mortality of COVID-19 patients. Detailed clinical history, laboratory parameters and therapeutics have been compared. There is no attrition as patients were followed till discharge or death. Despite the limitations of a small sample we were able to detect many predictors of mortality. The study is limited by data from a single-center with critically ill COVID-19 patients which may introduce a selection bias and inflate the mortality. Hence, results from this study may help in the risk stratification and management of similar critically ill patients only. The sample size is limited because of the number of beds available at the unit during the first wave. We plan to add more numbers in future as we are currently seeing the second wave. A larger multi-center cohort study from various hospitals of the country would help to further validate the findings of our study.

Figure 1: Flow and outcomes of COVID-19 suspects at the Indus Hospital Emergency (19th March-7th June 2020)

Table 1: Clinical characteristics of study participants by mortality

	Non-Survivors n(%)	Survivors n(%)	All patients	p-value
Age^{^^} (years)	61.4(54.1-69.1)	51.3(42.1-62.2)	57(45.3-65.1)	0.000 ^{**M}
Age (years)				
≤60	24(35.8)	74(62.2)	98(52.7)	0.000 ^{**P}
>60	43(64.2)	45(37.8)	88(47.3)	
Gender				
Male	52(77.6)	91(76.5)	148(76.9)	0.859 ^P
Female	15(22.4)	28(23.5)	43(23.1)	
Symptoms				
Fever	54(81.8)	91(77.8)	145(79.2)	0.155 ^{MC}
Cough	40(60.6)	67(57.3)	107(58.5)	
SOB	57(86.4)	88(75.2)	145(79.2)	
Runny nose	1(1.5)	4(3.4)	5(2.7)	
Sore Throat	3(4.5)	4(3.4)	7(3.8)	
Chest Pain	5(7.6)	4(3.4)	9(4.9)	
Fatigue	8(12.1)	7(6.0)	15(8.2)	
Diarrhea	4(6.1)	10(8.5)	14(7.7)	
Vomiting	2(3.0)	14(12.0)	16(8.7)	
Others	13(19.7)	33(28.2)	46(25.1)	
Total Duration of symptoms[^](days)	6(4-7)	7(4-10)	6(4-7)	0.121 ^M
Comorbid conditions				
None	13(19.4)	47(39.5)b	60(32.3)	0.007 ^{*M C}
Hypertension	35(52.2)	43(36.1)	78(41.9)	
Diabetes	35(52.2)	44(37.0)	79(42.5)	
Liver Disease	1(1.5)	0	1(0.5)	
Lung Disease	4(6.0)	3(2.5)	7(3.8)	
Renal Disease	6(9.0)	11(9.2)	17(9.1)	
Heart Disease	7(10.4)	11(9.2)	18(9.7)	
Other	18(26.9)	41(34.5)	59(31.7)	
Number of comorbid conditions				
≤2	43(79.6)	50(69.4)	93(73.8)	0.198 ^P
3-5	11(20.4)	22(30.6)	33(26.2)	
Clinical Signs at presentation				
Systolic Blood pressure[^] (mm/Hg)	144 (123-159)	134 (120-149)	138.5(121-153)	0.023 ^{*M}
Diastolic Blood pressure[^] (mm/Hg)	80(69-95)	79(72-89)	79.5(70-90)	0.982 ^M
Pulse^{^^}/minute	104.6 ± 22.4	99.9 ± 19.9	101.6 ± 20.9	0.141 ^T

Respiratory Rate[^]/m	32(26-38)	28(22-32)	28(24-36)	0.000 ^{**M}
Temperature[^] °F	98.6(98-99.1)	98.3(98-98.6)	98.6(98-98.6)	0.003 ^{*D}
Oxygen saturation[^] (%)	86(69-90)	93(86-96)	90(82-95)	0.000 ^{**M}
Oxygen Saturation (%)				
≥93	13(19.4)	62(52.1)	75 (40.3)	0.000 ^{*P}
<93	54(80.6)	57(47.9)	111 (59.7)	
GCS	15(15-15)	15(15-15)	15(15-15)	0.452 ^M
Disease Severity				
Asymptomatic	0	2(1.3)	2(1.1)	0.000 ^{**f}
Mild	0	13(10.9)	13(7.0)	
Moderate	0	18(15.1)	19(9.7)	
Severe	3(4.5)	13(10.9)	16(8.6)	
Critical	64(95.5)	73(61.3)	136(73.7)	
[^] Median (IQR), ^{^^} Mean±SD, *P-value<0.05, **P-value<0.0001, T: Independent sample T test, M: Mann Witney U test, P: Pearson Chi-Square, f: Fisher's Exact Test, MC: Chi-square for multiple Responses				
[^] Median (IQR), ^{^^} Mean±SD, *P-value<0.05, **P-value<0.0001, T: Independent sample T test, M: Mann Witney U test, P: Pearson Chi-Square, f: Fisher's Exact Test, MC: Chi-square for multiple Responses				

Table 2: Baseline laboratory parameters and Clinical severity scores by mortality				
Hemoglobin[^](gm/dl)	12.7(11.4-14.3)	13.1(11.6-14.1)	13(11.6-14.1)	0.894 ^M
Total WBC Count[^] (x10E9/L)	12.5(8.5-15.5)	9.9(6.9-13.9)	10.8(7.1-14.7)	0.021 ^{*M}
Neutrophils[^] (%)	86.3(81-91.2)	80.6(75-87.5)	83 (76.5-89)	0.000 ^{**M}
Lymphocytes[^] (%)	8.1(4.9-12.6)	12.2(7.8-18.1)	10.7(6.9-16.1)	0.000 ^{**M}
Eosinophils[^] (%)	0(0-0.1)	0.1(0-0.3)	0(0-0.2)	0.000 ^{**M}
Platelet Count[^] (x10E9/L)	198(147-296)	234.5(187-326)	232(169-323)	0.045 ^{*M}
ANC[^] (x10E9/L)	10.4(7.6-14.0)	7.9(5.3-11.6)	8.9(5.7-12.6)	0.006 ^{*M}
ALC[^] (x10E9/L)	0.9(0.5-1.3)	1.1(0.7-1.7)	1.0(0.7-1.7)	0.009 ^{*M}
ALC				
≤1	39(58.2)	52(44.1)	91(49.2)	0.064 ^{*P}
>1	28(41.8)	66(55.9)	94(50.8)	
NLR[^]	10.7(6.2-18.8)	6.7(4.2-11.2)	8.0(4.7-13.0)	0.000 ^{**M}
NLR				
<5	9(13.4)	43(36.1)	52(28.0)	0.001 ^{*P}
≥5	58(86.6)	76(63.9)	134(72.0)	
Arterial pH[^]	7.4(7.4-7.5)	7.4(7.4-7.5)	7.4(7.4-7.5)	0.421 ^M
PCO2 (mmHg)[^]	31.3(27.2-35.8)	31.9(28.5-34.7)	31.6(27.7-34.7)	0.777 ^M
PO2 (mmHg)[^]	50.2(41.9-63.5)	65.4(55.6-83.5)	60.4(47.3-76)	0.000 ^{**M}
PaO2/FiO2 Ratio[^]	156.8(77-233.3)	230.8(150.3-321.1)	195.4(121.3-287.4)	0.000 ^{**M}
ARDS				
Not Present	4(6.3)	34(32.1)	38(22.5)	0.001 ^{*P}
Mild	19(30.2)	28(26.4)	47(27.8)	
Moderate	22(34.9)	30(28.3)	52(30.8)	
Severe	18(38.6)b	14(13.2)a	32(18.9)	
Urea[^] (mg/dl)	45(34-71)	32(21-51)	36(24-55)	0.000 ^{**M}
Creatinine[^] (mg/dl)	1.2(1.0-1.8)	1(0.8-1.4)	1.1(0.9-1.5)	0.002 ^{*M}
Sodium[^] (mg/dl)	136(132-139)	137(134-139)	136(133-139)	0.311 ^M
Potassium[^](mg/dl)	4.1(3.7-4.6)	4.1(3.8-4.5)	4.1(3.7-4.5)	0.810 ^M
Bicarbonate[^] (mg/dl)	19(16-22)	20(18-22)	20(18-22)	0.130 ^M
Total Bilirubin[^] (mg/dl)	0.6(0.4-0.9)	0.6(0.4-0.8)	0.6(0.4-0.9)	0.417 ^M
SGPT[^] (U/L)	43(22-62)	32(19-69)	38(21-64)	0.475 ^M
Arterial Lactate[^] (mmol/L)	2.3(1.8-3.5)	1.7(1.3-2.3)	1.9(1.4-3.1)	0.001 ^{*M}
Serum Albumin[^] (g/L)	3.2(2.8-3.5)	3.4(3.1-3.6)	3.3(3.0-3.6)	0.014 ^{*M}
Prothrombin Time[^] (sec)	11.4(10.7-12.5)	11.5(10.9-12.1)	11.5(10.8-12.5)	0.997 ^M
APTT[^] (sec)	30.3(27.4-32.6)	26.9(24.8-32.4)	29.5(25.7-32.5)	0.068 ^M

Baseline CRP^ mg/L	175.5(86.8-261.7)	131.9(66.2-198.8)	145.4(78.0-219.1)	0.008 ^{*M}
CRP mg/L				
≤200	41(61.2)	88(75.2)	129(70.1)	0.046 ^{*P}
>200	26(38.8)	29(24.8)	55(29.9)	
Baseline D-dimer^ ng/ml	3729(1086-8763)	1257.5(615-4256)	1683(665-6858)	0.001 ^{*M}
Baseline LDH^ U/L	555.5(452-866)	398(312-512)	461(334-614)	0.000 ^{**M}
Baseline Ferritin^ ng/ml	1315(581.8-1675.6)	668.8(337.9-1557)	936.6(422.7-1675.6)	0.002 ^{*M}
Baseline IL-6^ pg/ml	78.6(34.9-362)	21.8(11.8-37.1)	35.8(20.8-107.5)	0.000 ^{**M}
Baseline Pro-calcitonin^ ng/ml	0.9(0.3-3.0)	0.3(0.1-0.7)	0.4(0.2-1.6)	0.000 ^{**M}
Baseline Troponin^ ng/ml	18(0-154)	6(3-20)	9.5(4-57)	0.000 ^{**M}
Blood culture				
Positive	5(8.3)	7(7.7)	12(7.9)	0.100 ^f
Negative	55(91.3)	84(92.3)	139(92.1)	
Non-invasive ventilation (in ER)				
Yes	38(56.7)	28(42.2)	66(35.5)	0.000 ^{**P}
No	29(43.3)	91(76.8)	120(63.2)	
CXR Findings				
Unilateral Radiologic Findings	3(4.8)	6(5.3)	9(5.1)	0.000 ^{**MC}
Bilateral Radiologic Findings	59(93.7)a	88(77.2)	147(83.1)	
Multilobar Infiltrates	36(57.1)a	30(26.3)	66(37.3)	
Consolidation	32(50.8)a	32(28.1)	64(36.2)	
Pleural Effusion	3(4.8)	7(6.1)	10(5.6)	
Others	7(11.1)	10(8.8)	17(9.6)	
Normal	0	16(14.0)	16(9.0)	
Clinical Severity Scores				
SOFA score^	6(5-8)	4(4-6)	5(4-8)	0.000 ^{**M}
CURB-65 score^	2(1-3)	1(0-2)	1(1-2)	0.000 ^{**M}
Mulbsta^	7(5-9)	4(0-7)	5.5(2-8)	0.000 ^{*M}
[^] Median (IQR), ^{^^} Mean±SD, [*] P-value<0.05, ^{**} P-value<0.0001, ^T : Independent sample T test, ^M : Mann Witney U test, ^P : Pearson Chi-Square, ^f : Fisher's Exact Test, ^{MC} : Chi-square for multiple Responses				

Table 3: Hospital course by mortality				
	Non-Survivors n(%)	Survivors n(%)	All patients	p-value
Treatment				
Methyl Prednisolone				
Yes	55(82.1)	85(73.3)	140(76.5)	0.207 ^P
No	12(17.9)	31(26.7)	43(23.5)	
Antibiotics				
Yes	63(94.0)	89(76.1)	152(82.6)	0.002 ^{*P}
No	4(6.0)	28(23.9)	32(17.4)	
Anticoagulation				
Therapeutic doses	43(64.2)	37(32.5)	80(44.2)	0.000 ^{**P}
Prophylactic doses	18(26.9)	63(55.3)	81(44.8)	
None	6(9.0)	14(12.3)	20(11.0)	
Hydroxychloroquine (HCQ)				
No	27(40.3)	65(54.6)	92(49.5)	0.068 ^P
Yes	40(59.7)	54(45.4)	94(50.5)	
Azithromycin (AZT)				
No	40(69.7)	94(79.0)	134(72.0)	0.003 ^{*P}
Yes	27(40.3)	25(21.0)	52(28.0)	
Tocilizumab (TCZ)				
Single Dose	13(19.4)	23(19.3)	36(19.4)	0.003 ^{*P}
Two Doses	8(11.9)b	1(0.8)a	9(4.8)	
Not Given	46(68.7)	95(79.8)	141(75.8)	
IVIg				
Single Dose	14(20.9)b	7(5.9)a	21(11.3)	0.000 ^{**f}
Multiple Doses	5(7.5)b	0a	5(2.7)	
Not Given	48(71.6)b	112(94.1)a	160(86.0)	
Azithromycin + HCQ				
No	40(69.7)	94(79.0)	134(72.0)	0.006 ^{*P}
Yes	27(40.3)	25(21.0)	52(28.0)	
Admission to ICU				
Yes	61(93.8)	38(34.2)	99(54.7)	0.000 ^{**P}
No	4(6.2)	73(65.8)	82(45.3)	
Invasive Ventilation				
Yes	58(86.6)	8(6.7)	66(35.5)	0.000 ^{**P}
No	9(13.4)	111(93.3)	120(64.5)	
In-Hospital complications				
None	10(14.9)	82(68.9)	92(49.5)	0.000 ^{**MC}

Cardiac	17(25.4)	10(8.4)	27(14.5)	
Nosocomial Infection	20(19.9)	11(9.2)	33(17.7)	
CNS	3(4.5)	2(1.7)	5(2.7)	
Septic Shock	30(44.8)	3(2.5)	33(17.7)	
MODS	24(34.3)	0	24(12.9)	
AKI	39(58.2)	9(7.6)	48(25.8)	
Thromboembolism	6(9.0)	1(0.8)	7(3.8)	
Barotrauma	3(4.5)	1(0.8)	4(2.2)	
DIC	9(13.4)	0	9(4.8)	
Sever Hyperglycemia	4(6.0)	3(2.5)	7(3.8)	
Electrolyte Imbalance	11(16.4)	4(3.4)	15(8.1)	
Other	7(10.4)	11(9.2)	18(9.7)	
Length of Hospital stay^ (days)	9(6-14)	7(4-10)	8(5-11)	0.007 ^{*M}
Length of ICU Stay^ (days)	9(5-12)	7(4-9)	7(4-10)	0.501 ^M
Days of Intubation^	6(3-9)	4.5(2-7)	6(2-9)	0.641 ^M
Cause of Death				
Respiratory Failure	22(35.5)			
Refractory shock	2(3.2)			
Multisystem Organ Failure (MSOF)	35(56.5)			
Other	3(4.8)			
^Median (IQR), ^^Mean±SD, *P-value<0.05, **P-value<0.0001, T: Independent sample T test, M: Mann Witney U test, P: Pearson Chi-Square, f: Fisher's Exact Test, MC: Chi-square for multiple Responses				

Table 4: Univariable binary logistic regression for predictors of in-hospital all-cause mortality			
	Crude OR	95% CI	p-value
Age >60 years	2.94	1.58 - 5.48	0.001
Gender (male)	1.06	.52- 2.18	0.859
Diabetes mellitus	1.86	1.02- 3.42058	0.04
Respiratory rate /min	1.08	1.04- 1.12	0.000
Temperature °F	1.50	1.14- 2.09	0.006
Oxygen saturation <93%	4.51	2.23- 9.14	0.000
SOFA	1.35	1.13- 1.61	0.001
CURB-65	1.96	1.43- 2.71	0.000
Mulbsta	1.24	1.14- 1.37	0.000
White blood cells (x10E9/L)	1.05	.99- 1.10	0.068
Neutrophils (%)	1.07	1.04- 1.12	0.000
Lymphocytes (%)	0.91	.87- .96	0.001
NLR>=5	3.64	1.65- 8.08	0.001
Platelets (x10E9/L)	0.99	.99- 1.00	0.076
Thrombocytopenia (yes)	11.6	1.37- 98.59	0.025
Lymphopenia (yes)	1.76	.96- 3.24	0.066
Multilobar involvement on CXR	3.44	1.83- 6.49	0.000
arterial pH	1.49	.06- 37.70	0.807
arterial PO2 mmHg	0.96	.94- .98	0.000
Pao2/Fio2 ratio	0.51	.37- .71	0.000
Creatinine mg/dl	0.96	.86- 1.08	0.54
Arterial lactate (mmol/L)	1.51	1.11- 2.05	0.009
Albumin g/L	0.34	.16- .72	0.005
CRP(>200) mg/L	1.92	1.01- 3.67	0.047
LDH U/L	1.00	.99- 1.00	0.215
D-dimer ng/ml	1.00	.99- 1.00	0.054
Ferritin ng/ml	1.00	1.00- 1.00	0.017
IL-6 pg/ml	0.99	.99- 1.00	0.048
Pro-calcitonin >2 ng/ml	3.23	1.48- 7.07	0.003
Troponin ng/ml	1.00	.99- 1.00	0.276
Antibiotics	4.95	1.65- 14.82	0.004
Anticoagulation			
No Anticoagulation	1		
Therapeutic anticoagulation	2.7	0.94-7.76	0.074
Prophylactic anticoagulation	0.66	0.224-1.98	
Use of Tocilizumab			

No	1		
Single dose	1.17	0.54-2.51	0.002
Double dose	16.5	2.01- 136.06	
IVIG	4.66	1.77- 12.29	0.002
ICU admission	29.29	9.90- 86.69	0.000
NIV in Emergency room	4.25	2.24-8.10	0.000
Invasive Ventilation	89.4	32.76- 244.01	0.000
Length of hospital stay (days)	1.03	.99- 1.08	0.114
Electrolyte abnormalities	5.6	1.72- 18.53	0.004
Sepsis	31.35	9.04-108.68	0.000
Cardiac complications	3.7	1.58- 8.67	0.003
Acute Kidney injury	17.0	7.3- 39.24	0.000

Figure 2: Multivariable Logistic regression model of all-cause mortality in COVID-19 patients

References

1. WHO. Timeline: WHO's COVID-19 response 2019 [Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline/#!>]
2. Worldometers. COVID-19 Coronavirus Pandemic. 2020.
3. Pakistan Go. Health Advisory 2020 [Available from: <https://covid.gov.pk/stats/pakistan>].
4. Banik A, Nag T, Chowdhury SR, Chatterjee R. Why Do COVID-19 Fatality Rates Differ Across Countries? An Explorative Cross-country Study Based on Select Indicators. *Global Business Review*. 2020;0972150920929897.
5. Organization WH. Clinical management of COVID-19: interim guidance, 27 May 2020. World Health Organization; 2020.
6. Nasir N, Habib K, Khanum I, Khan N, Muhammad ZA, Mahmood SFJAP. Predictors of severity and mortality of COVID-19 at a tertiary care center in a Lower-middle income country. 2020.
7. Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J. Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review. *PloS one*. 2012;7(4):e35797.
8. Wang Y, Lu X, Li Y, Chen H, Chen T, Su N, et al. Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19. *Am J Respir Crit Care Med*. 2020;201(11):1430-4.
9. Twigg III HL, Khan SH, Perkins AJ, Roberts S, Sears C, Rahman O, et al. Mortality Rates in a Diverse Cohort of Mechanically Ventilated Patients With Novel Coronavirus in the Urban Midwest. 2020;2(8).
10. Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. 2020;180(10):1345-55.
11. Audit IJA. ICNARC report on COVID-19 in critical care. 2020;10:2020.
12. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. 2020.
13. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med*. 2020;8(5):475-81.
14. Dondorp AM, Hayat M, Aryal D, Beane A, Schultz MJ. Respiratory Support in COVID-19 Patients, with a Focus on Resource-Limited Settings. *Am J Trop Med Hyg*. 2020;102(6):1191-7.
15. Slutsky AS, Ranieri VM. Ventilator-induced lung injury. *N Engl J Med*. 2013;369(22):2126-36.
16. Cates J, Lucero-Obusan C, Dahl RM, Schirmer P, Garg S, Oda G, et al. Risk for In-Hospital Complications Associated with COVID-19 and Influenza—Veterans Health Administration, United States, October 1, 2018–May 31, 2020. 2020;69(42):1528.
17. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. *Biology of Blood and Marrow Transplantation*. 2019;25(4):625-38.
18. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. 2020;323(11):1061-9.
19. Wu Z, McGoogan JMJ. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. 2020;323(13):1239-42.
20. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. 2020;369.

21. WSJ. Why Youthful, Conservative Pakistan Is a Coronavirus Bright Spot 2020 [Available from: <https://www.wsj.com/articles/why-youthful-conservative-pakistan-is-a-coronavirus-bright-spot-11596297600>].
22. CDC. COVID-19 (Coronavirus Disease) People at Increased Risk 2020 [Available from: <https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html>].
23. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med.* 2020;180(7):934-43.
24. Liu S, Yao N, Qiu Y, He C. Predictive performance of SOFA and qSOFA for in-hospital mortality in severe novel coronavirus disease. *The American Journal of Emergency Medicine.* 2020;38(10):2074-80.
25. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). *Clin Infect Dis.* 2020;71(15):732-9.
26. Medicine RCGJNEJo. Effect of hydroxychloroquine in hospitalized patients with Covid-19. 2020;383(21):2030-40.
27. FDA U. Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine. June; 2020.
28. Qureshi S, Naveed AB, Yousafzai MT, Ahmad K, Ansari S, Lohana H, et al. Response of extensively drug resistant Salmonella Typhi to treatment with meropenem and azithromycin, in Pakistan. *PLoS neglected tropical diseases.* 2020;14(10):e0008682.
29. Furtado RHM, Berwanger O, Fonseca HA, Correa TD, Ferraz LR, Lapa MG, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. *Lancet.* 2020;396(10256):959-67.
30. Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LC, Veiga VC, Avezum A, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. 2020;383(21):2041-52.
31. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. *JAMA.* 2020;323(24):2493-502.
32. Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. *Clin Infect Dis.* 2020;71(9):2459-68.
33. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19-preliminary report. 2020.
34. Sterne JA, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. *JAMA.* 2020;324(13):1330-41.
35. WHO/-nCoV/Corticosteroids/.1 WHOJWn. Corticosteroids for COVID-19. Living Guidance. 2020.
36. Jeronimo CMP, Farias MEL, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. 2020.
37. Malgic J, Schoones JW, Pijls BG. Decreased mortality in COVID-19 patients treated with Tocilizumab: a rapid systematic review and meta-analysis of observational studies. *Clin Infect Dis.* 2020.
38. Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, et al. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. 2020.
39. Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. *N Engl J Med.* 2020;383(24):2333-44.

40. Sarfaraz S, Shaikh Q, Iftikhar S, Herekar FF, Saleem SG, Kanani F. Is Tocilizumab an effective therapy for Severe COVID-19: a retrospective cohort study. 2020.